

International Conference
“CLINICAL GENETICS OF CANCER 2022”
Szczecin, 8th-9th December 2022
(Pomeranian Medical University in Szczecin, Rybacka 1)


Organisers / organizatorzy:

**Department of Genetics and Pathology, Pomeranian Medical
University in Szczecin**

**Zakład Genetyki i Patomorfologii Pomorskiego Uniwersytetu
Medycznego w Szczecinie**

**International Hereditary Cancer Center of Pomeranian Medical University
in Szczecin**

**Międzynarodowe Centrum Nowotworów Dziedzicznych Pomorskiego
Uniwersytetu Medycznego w Szczecinie**



Section of Clinical Genetics of Cancer of Polish Society of Human Genetics
**Sekcja Genetyki Klinicznej Nowotworów Polskiego Towarzystwa Genetyki
Człowieka**

Honorary patronage / Honorowy patronat:

**Marshal of the Zachodniopomorskie Voivodeship /
Marszałek Województwa Zachodniopomorskiego, Olgierd Geblewicz**



PATRONAT HONOROWY
MARSZAŁKA WOJEWÓDZTWA
ZACHODNIOPOMORSKIEGO
OLGIERDA GEBLEWICZA

**Rector of Pomeranian Medical University in Szczecin /
J.M. Rektor PUM, prof. dr hab. n. med. Bogusław Machaliński**



Patronat Honorowy Rektora
Pomorskiego Uniwersytetu Medycznego
w Szczecinie

**Regional Medical Chamber in Szczecin
Okręgowa Izba Lekarska w Szczecinie**



Sponsors / Sponsorzy:



**Ministerstwo
Edukacji i Nauki**



**Doskonała
Nauka**



Marszałek Województwa
Zachodniopomorskiego



**ANALITYK
GENETYKA**



ANALITYK



Perlan
a member of Altium Group

Thursday - 8th December 2022

8:45 - 9:00	Conference opening
9:00 - 9:30	Desmoid tumours, familial adenomatous polyposis and sporadic infiltrative fibromatosis (R. Scott, Newcastle)
9:30 - 10:00	The impact of genetic testing on surgical decision-making for colorectal cancer predisposition (G. Möslein, Duisburg)
10:00 - 10:30	Understanding of germline genetic basis of familial cancer (K. Hemminki, Pilsen, Heidelberg)
10:30 - 11:00	Genetic predisposition to colorectal cancer: Identification of novel cancer susceptibility genes (A. Försti, Heidelberg)
11:00 - 11:30	Coffee break
11:30 - 12:00	Mesalamine for Colorectal Cancer Prevention Program in Lynch syndrome (AS. Backman, Stockholm)
12:00 - 12:20	Screening and efficacy of sporadic and hereditary CRC detection in low incidence population (P. Elsakov, Vilnius)
12:20 - 12:35	Recommendation for preventive adnexectomy in MLH1 and MSH2 mutation carriers (M. Kuświk, Szczecin)
12:35 - 12:55	Update on spectrum and frequency of BRCA1/2, CHEK2 and TP53 variants in breast and ovarian cancer cohorts from Latvia (A. Irmejs, Riga)
12:55 - 13:50	Lunch
13:50 - 14:10	NGS in diagnostics of BRCA1/2 genes in patients with breast cancer (B. Wasag, Gdańsk)
14:10 - 14:30	Spectrum of mutations in BRCA1/2 detected by NGS in pancreatic cancer patients considered for treatment with PARP inhibitor (A. Kowalik, Kielce)
14:30 - 14:50	Simple method of detection of the most common PALB2 and RECQL genes mutations (A. Pławski, Poznań)
14:50 - 15:10	Characterization of liquid-biopsy based microRNA profiles of BRCA1/BRCA2 positive patients - a preliminary study (E. Kilar, M. Tokarski, Wrocław)
15:10 - 15:30	The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations (M. Szwiec, Opole)
15:30 - 15:50	The modification of response to treatment by non coding 3'UTR polymorphic variants in breast cancer patients (E. Grzybowska, Gliwice)
15:50 - 16:10	The latest advances in implantology of mammary gland in patients with breast cancer (D. Murawa, Zielona Góra)
16:10 - 16:40	Coffee break
16:40 - 17:00	PTEN-HTS – Genotype-phenotype correlations - a single institution's experience (D. Nowakowska, Warszawa)
17:00 - 17:20	Genetic susceptibility to prostate cancer, clinical implications (C. Cybulski, Szczecin)

17:20 - 17:40	Increasing significance of methylation biomarkers in clinical cancer management (T. Wojdacz, Szczecin)
17:40 - 18:00	Constitutional <i>BRCA1</i> promoter methylation and risk of ovarian cancer (A. Ogrodniczak, Szczecin)
18:00 - 18:15	Elements in cancer prevention (K. Białkowska, Szczecin)
18:15 - 18:30	Role of trace elements in early detection of cancer (S. Pietrzak, Szczecin)
18:30 - 18:45	Serum selenium levels in women with ovarian cancer (M. Kluza, Rzeszów)
18:45 - 19:00	Elements in cancer treatment (J. Lubiński, Szczecin)
19:00 – 19.15	SELINA – selenium level optimization with Sel-BRCA1® is lowering all-cause mortality in females with selenium deficiency (J. Lubiński, Szczecin)
19:15	Dinner

Friday - 9th December 2022

8:30 - 10:30	Meeting of Section of Clinical Genetics of Cancer of Polish Society of Human Genetics National Programme of Diagnostics and Surveillance in Families with Increased Predisposition to Cancers - analysis of current arrangements <ul style="list-style-type: none"> - report on the implementation of early detection and prevention programs for cancers in families with high hereditary risk of disease: Module I and Module II – in the group of patients covered by diagnostics and genetic counselling (B. Kałużewski, I. Kubiak, Łódź) - selected organizational aspects of management of families with high risk of cancers (A. Prusaczyk, Siedlce) - discussion (M. Stawicka, Poznań; J. Lubiński, Szczecin)
10:30 - 10:50	Coffee break
10:50 - 11:20	Education of oncologic patients about genetic alterations (S. Pogorzelska, Warszawa)
11:20 - 11:35	Educated patient is the value (A. Klimowicz-Nejman, OmeaLife Foundation)
11:35 - 11:55	Genetic testing as a necessary component of treatment planning in ovarian cancer at the age of PARP inhibitors (R. Mądry, Poznań)
11:55 -12:15	Possibilities of accounting for genetic tests on the example of BRCA-dependent cancers. A few words about HRD (A. Tysarowski, Warszawa)
12:15 - 12:35	Optimization of the genetic diagnostics algorithm in patients with ovarian cancer from south-eastern Poland (J. Gronwald, Szczecin)
12:35 - 12:55	CHEK2 mutations and the risk of papillary thyroid cancer (M. Siołek, Kielce)
12:55 - 13:15	The genetic risk of thyroid cancer among breast cancer patients (M. Cieszyńska, Szczecin)
13:15 - 14:15	Discussion of difficult cases
14:15	Closing Lunch